Zobrazeno 1 - 10
of 480
pro vyhledávání: '"G. Calaminus"'
Autor:
E. Aleshchenko, E. Swart, C. Spix, M. Voigt, P. Trocchi, T. Langer, G. Calaminus, K. Baust, J. Glogner, P. Ihle, J. Küpper-Nybelen, C. Lüpkes, T. Kloppe, D. Horenkamp-Sonntag, I. Meier, U. Marschall, P. Dröge, M. Klein, A. Weiss, C. Apfelbacher
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background It has been shown previously that a relevant proportion of childhood cancer survivors suffers from late effects, which are often directly related to the cancer itself or its therapy, resulting in particular follow-up needs, additi
Externí odkaz:
https://doaj.org/article/de27d846065e4c96adc3166711a71feb
Autor:
A. J. M. Meijer, F. A. Diepstraten, T. Langer, L. Broer, I. K. Domingo, E. Clemens, A. G. Uitterlinden, A. C. H. de Vries, M. van Grotel, W. P. Vermeij, R. A. Ozinga, H. Binder, J. Byrne, E. van Dulmen-den Broeder, M. L. Garrè, D. Grabow, P. Kaatsch, M. Kaiser, L. Kenborg, J. F. Winther, C. Rechnitzer, H. Hasle, T. Kepak, K. Kepakova, W. J. E. Tissing, A. L. F. van der Kooi, L. C. M. Kremer, J. Kruseova, S. M. F. Pluijm, C. E. Kuehni, H. J. H. van der Pal, R. Parfitt, C. Spix, A. Tillmanns, D. Deuster, P. Matulat, G. Calaminus, A. E. Hoetink, S. Elsner, J. Gebauer, R. Haupt, H. Lackner, C. Blattmann, S. J. C. M. M. Neggers, S. R. Rassekh, G. E. B. Wright, B. Brooks, A. P. Nagtegaal, B. I. Drögemöller, C. J. D. Ross, A. P. Bhavsar, A. G. am Zehnhoff-Dinnesen, B. C. Carleton, O. Zolk, M. M. van den Heuvel-Eibrink, the PanCareLIFE Consortium, and the CPNDS Consortium
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
Abstract In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893
Externí odkaz:
https://doaj.org/article/1a21ee1f4f0440f184693f4b2b482abf
Autor:
J. Salchow, J. Mann, B. Koch, J. von Grundherr, W. Jensen, S. Elmers, L. A. Straub, E. Vettorazzi, G. Escherich, S. Rutkowski, S. Dwinger, C. Bergelt, M. Sokalska-Duhme, S. Bielack, G. Calaminus, K. Baust, C. F. Classen, C. Rössig, J. Faber, H. Faller, I. Hilgendorf, J. Gebauer, T. Langer, M. Metzler, S. Schuster, C. Niemeyer, A. Puzik, D. Reinhardt, U. Dirksen, A. Sander, M. Köhler, J. K. Habermann, C. Bokemeyer, A. Stein
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Improved, multimodal treatment strategies have been shown to increase cure rates in cancer patients. Those who survive cancer as a child, adolescent or young adult (CAYA), are at a higher risk for therapy-, or disease-related, lat
Externí odkaz:
https://doaj.org/article/b28e888c177b403f97dc1d02560d907e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P Trocchi, E Swart, E Aleshchenko, C Spix, M Voigt, C Lüpkes, P Ihle, J Küpper-Nybelen, I Meier, D Horenkamp-Sonntag, P Dröge, U Marschall, M Klein, G Calaminus, K Baust, T Langer, C Apfelbacher
Publikováno v:
Das Gesundheitswesen.
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:1068
Autor:
Wim J. E. Tissing, J Kruseova, A E Hoetink, G Calaminus, R Haupt, I K Domingo, E van Dulmen-den Broeder, Amit P. Bhavsar, J Byrne, H Hasle, C Spix, S Elsner, A P Nagtegaal, L Kenborg, J Gebauer, O Zolk, S M F Pluijm, A J M Meijer, H Binder, R A Ozinga, C Rechnitzer, S J C M M Neggers, M L Garrè, P Matulat, D Deuster, T Langer, Britt I. Drögemöller, H. J. H. van der Pal, D Grabow, Leontien C. M. Kremer, Galen E.B. Wright, E Clemens, A.L.F. van der Kooi, M Kaiser, Bruce Carleton, F A Diepstraten, J F Winther, C Blattmann, L Broer, M van Grotel, R Parfitt, A G Am Zehnhoff-Dinnesen, K Kepakova, H Lackner, M M van den Heuvel-Eibrink, Shahrad Rod Rassekh, T Kepak, A. C. H. de Vries, Beth Brooks, André G. Uitterlinden, C. E. Kuehni, A Tillmanns, Wilbert P. Vermeij, Colin J. D. Ross, P Kaatsch
Publikováno v:
37. Wissenschaftliche Jahrestagung der Deutschen Gesellschaft für Phoniatrie und Pädaudiologie (DGPP); 20210917-20210918; sine loco [digital]; DOCP15 /20211028/
The PanCareLIFE Consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, no. 1, 64 . https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, Diepstraten, F A, Langer, T, Broer, L, Domingo, I K, Clemens, E, Uitterlinden, A G, de Vries, A C H, van Grotel, M, Vermeij, W P, Ozinga, R A, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, M L, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, J F, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, W J E, van der Kooi, A L F, Kremer, L C M, Kruseova, J, Pluijm, S M F, Kuehni, C E, van der Pal, H J H, Parfitt, R, Spix, C, Tillmanns, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, A E, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, S J C M M, Rassekh, S R, Wright, G E B, Brooks, B, Nagtegaal, A P, Drögemöller, B I, Ross, C J D, The PanCareLIFE consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, no. 1, 64 . https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, Diepstraten, F A, Langer, T, Broer, L, Domingo, I K, Clemens, E, Uitterlinden, A G, de Vries, A C H, van Grotel, M, Vermeij, W P, Ozinga, R A, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, M L, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, J F, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, W J E, van der Kooi, A L F, Kremer, L C M, Kruseova, J, Pluijm, S M F, Kuehni, C E, van der Pal, H J H, Parfitt, R, Spix, C, Tillmanns, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, A E, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, S J C M M, Rassekh, S R, Wright, G E B, Brooks, B, Nagtegaal, A P, Drögemöller, B I, Ross, C J D, the PanCareLIFE Consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, 64 . https://doi.org/10.1038/s41698-021-00178-z
npj Precision Oncology, 5(1):64. Springer Nature
Meijer, A J M; Diepstraten, F A; Langer, T; Broer, L; Domingo, I K; Clemens, E; Uitterlinden, A G; de Vries, A C H; van Grotel, M; Vermeij, W P; Ozinga, R A; Binder, H; Byrne, J; van Dulmen-den Broeder, E; Garrè, M L; Grabow, D; Kaatsch, P; Kaiser, M; Kenborg, L; Winther, J F; ... (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), p. 64. Springer Nature 10.1038/s41698-021-00178-z
NPJ Precision Oncology
NPJ precision oncology, 5(1):64, 1-8. Nature Research
npj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
The PanCareLIFE Consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, no. 1, 64 . https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, Diepstraten, F A, Langer, T, Broer, L, Domingo, I K, Clemens, E, Uitterlinden, A G, de Vries, A C H, van Grotel, M, Vermeij, W P, Ozinga, R A, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, M L, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, J F, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, W J E, van der Kooi, A L F, Kremer, L C M, Kruseova, J, Pluijm, S M F, Kuehni, C E, van der Pal, H J H, Parfitt, R, Spix, C, Tillmanns, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, A E, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, S J C M M, Rassekh, S R, Wright, G E B, Brooks, B, Nagtegaal, A P, Drögemöller, B I, Ross, C J D, The PanCareLIFE consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, no. 1, 64 . https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, Diepstraten, F A, Langer, T, Broer, L, Domingo, I K, Clemens, E, Uitterlinden, A G, de Vries, A C H, van Grotel, M, Vermeij, W P, Ozinga, R A, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, M L, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, J F, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, W J E, van der Kooi, A L F, Kremer, L C M, Kruseova, J, Pluijm, S M F, Kuehni, C E, van der Pal, H J H, Parfitt, R, Spix, C, Tillmanns, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, A E, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, S J C M M, Rassekh, S R, Wright, G E B, Brooks, B, Nagtegaal, A P, Drögemöller, B I, Ross, C J D, the PanCareLIFE Consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, 64 . https://doi.org/10.1038/s41698-021-00178-z
npj Precision Oncology, 5(1):64. Springer Nature
Meijer, A J M; Diepstraten, F A; Langer, T; Broer, L; Domingo, I K; Clemens, E; Uitterlinden, A G; de Vries, A C H; van Grotel, M; Vermeij, W P; Ozinga, R A; Binder, H; Byrne, J; van Dulmen-den Broeder, E; Garrè, M L; Grabow, D; Kaatsch, P; Kaiser, M; Kenborg, L; Winther, J F; ... (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), p. 64. Springer Nature 10.1038/s41698-021-00178-z
NPJ Precision Oncology
NPJ precision oncology, 5(1):64, 1-8. Nature Research
npj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
Background: Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of cisplatin treatment in children with cancer. The heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87b1abb74a67b5c6ca531ead07151865
http://www.egms.de/en/meetings/dgpp2021/21dgpp30.shtml
http://www.egms.de/en/meetings/dgpp2021/21dgpp30.shtml
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.